Retinal Vein Occlusion Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Rip

Retinal Vein Occlusion Pipeline constitutes 15+ key companies continuously working towards developing 15+ Retinal Vein Occlusion treatment therapies, analyzes DelveInsight.

Retinal Vein Occlusion Overview:

Retinal vein occlusion (RVO) is the second most prevalent retinal vascular disease and a common cause of vision loss in older adults. It is classified into two types: branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). CRVO occurs when the main retinal vein becomes blocked behind the lamina cribrosa of the optic nerve, typically due to thrombosis. CRVO is further categorized into two forms: non-ischemic (perfused) and ischemic (non-perfused), with non-ischemic CRVO being the most common, accounting for approximately 70% of cases.

Age is a primary risk factor for CRVO, with 90% of cases occurring in individuals over 50. Other major risk factors include systemic arterial hypertension, open-angle glaucoma, diabetes mellitus, and hyperlipidemia. Additional contributing factors include smoking, optic disc drusen, optic disc edema, and various hypercoagulable states such as polycythemia, multiple myeloma, cryoglobulinemia, Waldenström macroglobulinemia, antiphospholipid syndrome, Leiden factor V mutation, activated protein C resistance, hyperhomocysteinemia, and deficiencies in Protein C, Protein S, or antithrombin III. Other associated conditions include syphilis, sarcoidosis, sickle cell disease, HIV, vasculitis, and certain medications like oral contraceptives or diuretics. Rarely, migraines and orbital diseases may also contribute to the development of CRVO.

Request for a detailed insights report on Retinal Vein Occlusion pipeline insights @ https://www.delveinsight.com/report-store/retinal-vein-occlusion-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Retinal Vein Occlusion Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Retinal Vein Occlusion Therapeutics Market.

Key Takeaways from the Retinal Vein Occlusion Pipeline Report

DelveInsight's Retinal Vein Occlusion pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Retinal Vein Occlusion treatment.
Key Retinal Vein Occlusion companies such as Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys, and others are evaluating new drugs for Retinal Vein Occlusion to improve the treatment landscape.
Promising Retinal Vein Occlusion pipeline therapies in various stages of development include KSI-301, 601, IBE-814, and others.

Recent breakthroughs in the Retinal Vein Occlusion Pipeline Segment:

In December 2025, Regeneron and Bayer announced that Eylea HD (aflibercept 8 mg) met its primary endpoint in a Phase III trial for macular edema following RVO. Patients receiving Eylea HD every eight weeks achieved non-inferior visual acuity gains compared to those receiving the original Eylea formulation every four weeks. This suggests that Eylea HD may offer extended dosing intervals, potentially reducing the treatment burden for patients. Regeneron plans to submit these findings to the FDA in the first quarter of 2025, aiming to expand Eylea HD's indications to include RVO.
In October 2023, the U.S. Food and Drug Administration (FDA) approved Genentech's Vabysmo (faricimab-svoa) for the treatment of macular edema following RVO. This approval was based on positive results from the Phase III BALATON and COMINO studies, which demonstrated that monthly Vabysmo injections provided early and sustained vision improvements in patients with branch and central RVO. The studies met the primary endpoint of non-inferior visual acuity gains at 24 weeks compared to aflibercept, with Vabysmo also achieving rapid and robust retinal fluid reduction. The safety profile of Vabysmo was consistent with previous trials, with conjunctival hemorrhage being the most common adverse reaction (3%).

Retinal Vein Occlusion Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Retinal Vein Occlusion Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Retinal Vein Occlusion treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Retinal Vein Occlusion market.

Download our free sample page report on Retinal Vein Occlusion pipeline insights @ https://www.delveinsight.com/sample-request/retinal-vein-occlusion-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Retinal Vein Occlusion Emerging Drugs

KSI-301: Kodiak sciences
601: Sunshine Guojian Pharmaceutical
IBE-814: Ripple Therapeutics

Retinal Vein Occlusion Companies

Around 15 or more major companies are actively developing therapies for Retinal Vein Occlusion. Among them, Kodiak Sciences has a drug candidate in the mid-to-advanced stage of development, specifically in Phase III clinical trials.

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Retinal Vein Occlusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Retinal Vein Occlusion Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Retinal Vein Occlusion Therapies and Key Companies: Retinal Vein Occlusion Clinical Trials and advancements @ https://www.delveinsight.com/report-store/retinal-vein-occlusion-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Retinal Vein Occlusion Pipeline Therapeutic Assessment
• Retinal Vein Occlusion Assessment by Product Type
• Retinal Vein Occlusion By Stage
• Retinal Vein Occlusion Assessment by Route of Administration
• Retinal Vein Occlusion Assessment by Molecule Type

Download Retinal Vein Occlusion Sample report to know in detail about the Retinal Vein Occlusion treatment market @ Retinal Vein Occlusion Therapeutic Assessment @ https://www.delveinsight.com/sample-request/retinal-vein-occlusion-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Retinal Vein Occlusion Current Treatment Patterns
4. Retinal Vein Occlusion - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Retinal Vein Occlusion Late-Stage Products (Phase-III)
7. Retinal Vein Occlusion Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Retinal Vein Occlusion Discontinued Products
13. Retinal Vein Occlusion Product Profiles
14. Retinal Vein Occlusion Key Companies
15. Retinal Vein Occlusion Key Products
16. Dormant and Discontinued Products
17. Retinal Vein Occlusion Unmet Needs
18. Retinal Vein Occlusion Future Perspectives
19. Retinal Vein Occlusion Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Retinal Vein Occlusion Pipeline Reports Offerings: https://www.delveinsight.com/report-store/retinal-vein-occlusion-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.